A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function

Official title

A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-COHORT STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF PF-07328948 IN ADULTS WITH RENAL IMPAIRMENT AND HEALTHY ADULT PARTICIPANTS WITH NORMAL RENAL FUNCTION

Overview

The purpose of this study is to learn how the study medicine PF-07328948 is processed by the body and how safe and tolerable it is in adults with different levels of kidney function. The study will include participants who: * Are aged 18 to 80 years. * Either have normal kidney function or long-term reduced kidney function (moderate or severe). * Have a BMI (body mass index) of 17.5 to 40 kilogram per meter squared, inclusive, and a total body weight of more than or equal to 45 kilograms or 99 pounds. All participants will receive a single dose of PF-07328948 as a tablet taken by mouth. Participants will stay at a clinical research unit for about 6 days to receive the study medicine and undergo safety checks. Total participation lasts up to 64 days, including screening, inpatient stay, and a follow-up call. The study is not randomized or blinded, meaning all participants and study staff know which treatment is being given. Group assignment is based on kidney function tests done during screening. The results will help researchers understand how reduced kidney function affects the way PF-07328948 works in the body.

Interventions

• Drug PF-07328948
  PF-07328948 , 1 tablet orally, once on Day 1

Primary outcome measures

• Fraction of Unbound Drug in Plasma (Fu) of PF-07328948 [Time frame: At 0 (prior to dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose on Day 1]
• Unbound AUCinf (AUCinf,u) of PF-07328948 [Time frame: At 0 (prior to dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose on Day 1]
• Unbound Cmax (Cmax,u) of PF-07328948 [Time frame: At 0 (prior to dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose on Day 1]

Secondary outcome measures (1)

• Number of Participants with Treatment Emergent Adverse Events (TEAEs) [Time frame: Day 1 to Day 36]

Eligibility criteria

Inclusion criteria

• Male or female of nonchildbearing potential, between the ages of 18 and 80 years, at the screening visit.
• BMI of 17.5 to 40.0 kg/m2 (inclusive), and a total body weight ≥45 kg (99 lbs).
• Stable renal function, defined as ≤25% difference between 2 measurements of eGFR.
• Group 1 only: at screening, no clinically relevant abnormalities identified by a detailed medical history, physical exam, including blood pressure and pulse rate measurement, ECG and clinical laboratory tests.
• Group 1 only: normal renal function (mean eGFR ≥90 mL/min) based on an average of measures from the screening visits.
• Groups 2 \& 3 only: good general health considered acceptable with the expected health status of individuals with chronic renal impairment.
• Groups 2 \& 3 only: chronic renal impairment, defined by the following mean eGFR criteria (based on screening visits):

• Severe RI: 15 ≤ mean eGFR <30 mL/min, not requiring hemodialysis.
• Moderate RI: 30 ≤ mean eGFR <60 mL/min.

Exclusion criteria

• Any condition possibly affecting drug absorption.
• At screening, a positive result for HIV antibodies.
• History of renal, liver, or heart transplantation.
• Urinary incontinence without catheterization.
• Evidence of a prothrombotic state, including history of deep vein thrombosis, pulmonary embolism, or arterial thrombosis, or known genetic predisposition.
• Use of an investigational product within 30 days or 5 half-lives (whichever longer).
• A positive urine drug test or breath alcohol test at screening or admission to study clinic.
• Group 1 only: evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
• Group 1 only: screening ECG demonstrating QTcF interval >450 ms or a QRS interval >120 ms.
• Group 1 only: screening seated systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg
• Group 2 \& 3 only: presence of acute renal disease
• Group 2 \& 3 only: requiring dialysis or anticipated need for dialysis
• Group 2 \& 3 only: listed for solid organ transplantation
• Groups 2 \& 3 only: persistent severe, uncontrolled hypertension at screening, admission to study clinic, or pre-dose on Day 1.
• Groups 2 \& 3 only: screening ECG demonstrating a QTcF interval >470 ms or a QRS interval >120 ms.
• Groups 2 \& 3 only: unstable medical conditions or comorbidities that would interfere with study participation

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation

Non-randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Basic science

Study locations

United States · 4 centers

• Orange County Research Center — Lake Forest
• Orlando Clinical Research Center — Orlando
• Genesis Clinical Research, LLC — Tampa
• Nucleus Network — Saint Paul

Identifiers

NCT: NCT07315360 · C4921014 · C4921014

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗